Floatz logo

Adxs31-164

HER2 Expressing Solid Tumors

Advaxis, Inc.Phase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the HER2 Expressing Solid Tumors cohort.

Asset / SponsorPhaseRating
VNX-202
Vironexis Biotherapeutics Inc.
Phase 1/2CCC

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →